The Global Drug And Gene Delivery Devices Market Growth Accelerated By Bioprinting Trends

 

Drug and gene delivery devices are instruments that deliver therapeutic substances such as drugs, biologics, and genes into patients' bodies for localized treatment. Some examples of drug and gene delivery devices include injector pens, transdermal patches, nebulizers, and 3D printed devices. The global drug and gene delivery devices market is growing rapidly due to the increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases. 3D bioprinting technology enables the development of personalized drug delivery systems by depositing multiple cell types and growth factors layer-by-layer with high precision.

The global Drug and Gene Delivery Devices Market is estimated to be valued at US$ 169.3 Billion in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing adoption of 3D bioprinting technology is expected to drive the growth of the drug and gene delivery devices market over the forecast period. 3D bioprinting allows complex structures like tissue and organs to be printed for pharmaceutical and biomedical applications. It gives product designers more control over geometry, anatomy and design of delivery devices. Researchers are exploring the potential of 3D printing for developing personalized drug release platforms with complex internal architectures and multiple active ingredients. Bioprinting is also being used to fabricate miniaturized implantable devices with custom shapes and multiple compartments for controlled release of drugs. The advanced technology offers immense opportunities for designing innovative drug and gene delivery systems with clinical efficacy.

Segment Analysis
The global drug and gene delivery devices market is dominated by oral delivery systems segment. Oral delivery systems provide more flexibility and convenience in drug administration. Being non-invasive, oral delivery systems are preferred by people for self-administration of drugs and therapeutics. Various advantages such as ease of use and administration, flexibility in dose, and cost-effectiveness have made oral delivery systems highly popular among patients as well as healthcare providers.

Key Takeaways
The Global Drug And Gene Delivery Devices Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Drug and Gene Delivery Devices Market is estimated to be valued at US$ 169.3 Billion in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023 to 2030.

Regional analysis
North America region holds the highest share in the global drug and gene delivery devices market owing to presence of developed healthcare infrastructure and availability of advanced technologies. However, Asia Pacific region is witnessing rapid growth and is expected to grow at the highest CAGR during the forecast period. Rising geriatric population, increasing incidence of chronic diseases, growing healthcare expenditure, and improving access to healthcare are some of the key factors contributing to the fast growth of drug and gene delivery devices market in Asia Pacific region.

Key players

Key players operating in the drug and gene delivery devices market are 3D Systems Corporation, Cyfuse Biomedical KK, GeSIM GmbH, 3D Bioprinting Solutions, Aspect Biosystems Ltd., Organovo Holdings Inc., ARCAM AB, Cellink AB, RegenHU SA, REGEMAT 3D, EnvisionTEC GmbH and Stratasys Ltd. These companies are focused on developing advanced drug and gene delivery solutions through technological innovations and strategic collaborations. For instance, in 2022, Organovo collaborated with Celigo Therapeutics to develop ex vivo lung tissue models for preclinical testing of gene and cell therapies for lung diseases.

For More Insights, Read: https://www.newsstatix.com/drug-and-gene-delivery-devices-market-size-share-and-growth-forecast-2023-2030/